Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 34, Issue 2, 1996, Pages 303-308

  Jeremic, Branislav ^a   Shibamoto, Yuta ^b  

^a University Hospital

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Hyperfractionation; Interfraction interval; Nonsmall cell lung cancer; Radiotherapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030061459     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02158-2     Document Type: Article

References (18)

1. Ball, D.; Bishop, J.; Smith, J.; Crennan, E.; O'Brien, P.; Davis, S.; Ryan, G.; Joseph, D.; Walker, Q. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: An interim toxicity analysis of the first 100 patients. Int. J. Radiat. Oncol. Biol. Phys. 31:267-272; 1995.
2. Byhardt, R. W.; Pajak, T. F.; Emami, B.; Herskovic, A.; Doggett, R. S.; Olsen, L. A. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung : Report of Radiation Therapy Oncology Group 84-07. Int. J. Radiat. Oncol. Biol. Phys. 26:459-468; 1993.
3. Cox, J. D.; Azarnia, N.; Byhardt, R. W.; Shin, K. H.; Emami, B.; Pajak, T. F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with > 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III nonsmall cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J. Clin. Oncol. 8: 1543-1555; 1990.
4. Cox, J. D.; Pajak, T. F.; Marcial, V. A.; Coia, L.; Mohiuddin, M.; Fu, K. K.; Selim, H.; Rubin, P.; Ortiz, H. and the Radiation Therapy Oncology Group. Interfraction interval is a major determinant of late effects with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: Results from Radiation Therapy Oncology Group protocol 83-13. Int. J. Radiat. Oncol. Biol. Phys. 20:1191-1195; 1991.
5. Fowler, J. F. Intervals between multiple fractions per day. Differences between early and late radiation reactions. Acta Oncol. 27:181-183; 1988.
6. Fowler, J. F. Are half-times of repair reliably shorter for tumors than for late normal-tissue effects? Int. J. Radiat. Oncol. Biol. Phys. 31:189-190; 1995.
7. Hopewell, J. W.; van den Aardweg, G. J. M. J. Current concepts of dose-fractionation in radiotherapy: Normal tissue tolerance. Br. J. Radiol. (Suppl. 22): 88-94; 1988.
8. Jeremic, B.; Grujicic, D.; Antunovic, V.; Djuric, L.; Shibamoto, Y. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma. A phase II study. Int. J. Radiat. Oncol. Biol. Phys. 30:1179-1185; 1994.
9. Jeremic, B.; Shibamoto, Y.; Acimovic, L.; Djuric, L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for Stage III nonsmall-cell lung cancer. J. Clin. Oncol. 13:452-458; 1995.
10. Kleineidam, M.; Pieconka, A.; Beck-Bornholdt, H. P. Radiotherapy of the rhabdomyosarcoma R1H of the rat: Influence of the time interval between two daily fractions during hyperfractionated radiotherapy. Radiother. Oncol. 30:128-132; 1994.
11. Marcial, V. A.; Pajak, T. F.; Chang, C.; Tupchong, L.; Stetz, J. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (Preliminary report) by the Radiation Therapy Oncology Group (RTOG). Int. J. Radiat. Oncol. Biol. Phys. 13: 41-47; 1987.
12. Morgan, D. A. L.; Bradley, P. J.; MacLennan, K. A. Radiotherapy of advanced laryngeal cancer using three fractions per day. Br. J. Radiol. 60:607, 1987.
13. Nelson, D. F.; Curran, W. J.; Scott, C.; Nelson, J. S.; Weinstein, A. S.; Ahmad, K.; Constine, L.; Murray, K.; Powlis, W. D.; Mohiuddin, M.; Fischbach, J. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - Possible advantage observed at 72.0 Gy in 1.2 b.i.d. fractions: Report of the Radiation Therapy Oncology Group protocol 8302. Int. J. Radiat. Oncol. Biol. 25:193-207; 1993.
14. Rojas, A.; Joiner, M. C. The influence of dose per fraction on repair kinetics. Radiother. Oncol. 14:329-336; 1989.
15. Saunders, M. I.; Dische, S. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in nonsmall cell carcinoma of the bronchus. Int. J. Radiat. Oncol. Biol. Phys. 19:1211-1215; 1990.
16. Seagren, S. L.; Herndon, J. E.; Backer, J. R.; Boles, M.; Chung, C.; Green, M. R. Alternating irradiation and chemotherapy in Stage III A and B nonsmall cell lung cancer: Report of a Cancer and Leukemia Group B phase II study. Int. J. Radiat. Oncol. Biol. Phys. 29:1085-1089; 1994.
17. Shaw, E. G.; Deming, R. L.; Creagan, E. T.; Nair, S.; Su, J. Q.; Levitt, R.; Steen, P. D.; Wiesenfeld, M.; Mailliard, J. A. Pilot study of human recombinant Interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable Stage IIIA/B nonsmall cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 31:827-831; 1995.
18. Thames, H. D.; Withers, H. R.; Peters, L. J. Tissue repair capacity and repair kinetics deduced from multifractionated or continuous regimens with incomplete repair. Br. J. Cancer 49 (Suppl. VI):263-269; 1984.